Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- “New Rules” for Expensive Drugs Could Impact Business Models: Health Insurance Bureau Chief
July 8, 2016
- Number of Academia-Originated Drugs Highest in Oncology: AMED Survey
July 7, 2016
- Imusera/Gilenya Don’t Delay Disability Progression in Primary Progressive MS, MHLW Orders Label Revisions
July 6, 2016
- MHLW OKs Sanofi’s PCSK9 Inhibitor, Other Drugs
July 5, 2016
- MHLW to Issue “Blue Book” on Quality of Generics by March-End
July 1, 2016
- It’s Now Up to UK Govt to Decide on Future Action after Brexit Vote: EMA Spokesperson
June 30, 2016
- MHLW Begins Interim Review of 10-Year Strategy on Hepatitis Research
June 29, 2016
- MHLW Restresses Risk of HBV Reactivation for 8 Hep C Drugs
June 29, 2016
- Key Govt Panel Meets to Discuss Brexit’s Impact on Industries
June 29, 2016
- AMED Sets Up First Overseas Outpost in Singapore
June 28, 2016
- MHLW Vows to Forge Ties with UK Counterpart in Post-Brexit Regulations
June 27, 2016
- JEC Rengo Petitions MHLW to Eliminate “Huge-Seller” Repricing in Its Policy Proposal
June 27, 2016
- Panel to Discuss Zoster Vaccine’s Add’l Use, DPT Vaccine’s Booster Dose for Public Immunization Program
June 24, 2016
- Registration System for Prevention of Dementia to Begin Operation; Will Provide Info on Clinical Research, Trials
June 24, 2016
- MHLW Official Vows to Swiftly Present Proposal on “Optimal Use of Innovative Drugs”: Chuikyo
June 23, 2016
- Chuikyo OKs NHI Price Listing of Anti-HIV Drug Genvoya
June 23, 2016
- Exemption from Bioequivalence Studies Adopted as New Topic at ICH Meeting in Lisbon; Could Affect Generics as Well
June 22, 2016
- Selexipag Designated as Orphan Drug for CTEPH: MHLW
June 21, 2016
- PMDA to Boost Transparency in Expert Consultation Process by Confirming Donations from Competitors
June 21, 2016
- PMDA Beats FY2015 Review Time Targets
June 20, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…